The National Institutes of Health (NIH) announced yesterday the release of $45 million in new funds to support trials targeting drug development and prevention of Alzheimer's disease (AD).
The studies are among the first to be developed under the direction of a federal initiative for tackling the disease, mandated as part of the National Alzheimer's Project Act. As part of that effort, a core group of Alzheimer's specialists, patients, families and advocacy organizations, met in May 2012 — for the Alzheimer's Disease Research Summit 2012 — to outline research goals and priorities and develop the National Plan to Address Alzheimer's Disease.
In June, the Department of Health and Human Services published updated goals on the initiative — among them, to identify prevention and treatment strategies for AD by 2025; improve patient care; enhance support networks for patients and their families; and increase public awareness; and carefully track data for these efforts.
“We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer's biology and find effective therapies as quickly as possible,” NIH Director Francis S. Collins, MD, PhD, said in a press statement. The majority of the funding ($40 million) comes from the Office of the NIH Director, with additional funding from the National Institute on Aging (NIA).
For the full descriptions of the trials funded, see http://1.usa.gov/15CzZuJ Visit Neurology Today's archives for our past coverage of Alzheimer's disease research: http://bit.ly/1clb02K, and for more on national Alzheimer's initiatives: http://bit.ly/14mp8nJ.
For more on Neurology Today's daily news updates, see neurotodayonline.com.